期刊文献+

As_2O_3为基础的联合方案治疗非霍奇金淋巴瘤 被引量:2

下载PDF
导出
摘要 目的:评价三氧化二砷(As2O3)为基础的联合方案治疗非霍奇金淋巴瘤(NHL)的应用价值并探讨其作用机制,探索新疗法。方法:5例NHL患者应用亚砷酸注射液联合地塞米松、维生素C治疗,治疗过程中观察疗效及不良反应并动态监测血清VEGF、MMP-9含量变化。结果:5例患者中4例有效。所有患者均出现肝功能损伤,部分出现消化道症状、轻度血细胞下降、口周麻木等不良反应。3例B细胞型患者的VEGF值下降而2例富于T细胞的B细胞型患者上升,4例治疗有效患者MMP-9值下降而1例PD患者上升。结论:As2O3为基础的联合方案对NHL有一定治疗效果,通过下调VEGF、MMP-9从而抑制血管新生可能是其作用机制之一,As2O3对VEGF水平的效应在不同细胞型NHL中可能不同而对MMP-9水平的效应与疗效相关。
出处 《临床血液学杂志》 CAS 2009年第1期47-49,共3页 Journal of Clinical Hematology
基金 云南省教育厅基金(No:04z009c)
  • 相关文献

参考文献8

  • 1陈灏珠.实用内科学[M] 11版[M].北京:人民卫生出版社,2001.979-980.
  • 2喻镁佳,段勇,刘华,张学美,李惠民.As_2O_3抑制人淋巴瘤Raji细胞增殖及VEGF表达[J].中国实验血液学杂志,2006,14(4):704-707. 被引量:6
  • 3许晓巍,许小平,易克,陈莉,陈少谊,周芳,李倩玉.地塞米松对三氧化二砷诱导淋巴瘤细胞凋亡与NF-κB活化及相关基因表达的影响[J].中华血液学杂志,2005,26(4):227-231. 被引量:15
  • 4DAI J, WEINBERG R S, WAXMAN S, et al. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system [J]. Blood, 1999; 93: 268-277.
  • 5GRAD J M, BAHLIS N J, REIS I, et al. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells[J]. Blood, 2001, 98: 805-813.
  • 6PEDERSEN L M, KLAUSEN T W, DAVIDSEN U H, et al. Early changes in serum IL-6 and VEGF levels predict clinical outcome following first line therapy in aggressive non-Hodgkin's lymphoma[J]. Ann Hematol, 2005,84: 510-516.
  • 7NIITSU N, OKAMATO M, NAKAMINE H, et al. Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non- Hodgkin'lymphoma[J]. Eur J Haematol, 2002, 68: 91-100.
  • 8SALVEN P, ORPANA A, TEERNHOVI L. Simultaneous elevation in the serum concentration8 of the angiogenic growth factors VEGF and bFGF is an independent predictors of poor prognosis in non-Hodgkin lym-phoma : a single institution study of 200 patients [J]. Blood, 2000, 96: 3712-3718.

二级参考文献18

  • 1Bode AM, Dong Z. The paradox of arsenic: molecular mechanisms of cell transformation and chemotherapeutic effects. Crit Rev Oncol Hematol,2002 ,42 :5-24.
  • 2Turco MC, Romano MF, Petrella A, et al. NF-κB /Rel-mediated regulation of apoptosis in hematologic malignancies and normal hematopoietic progenitors. Leukemia ,2004,18:11-17.
  • 3Fujioka S, Sclabas GM, Schmidt C, et al. Inhibition of constitutive NF-κB activity by IκBαM suppresses tumorigenesis. Oncogene,2003,22:1365-1370.
  • 4Waalkes MP, Fox DA, States JC, et al. Metals and disorders of cell accumulation: modulation of apoptosis and cell proliferation. Toxicol Sci, 2000,56:255-261.
  • 5Hu Y, Jin X, Snow ET. Effect of arsenic on transcription factor AP1 and NF-κB DNA binding activity and related gene expression. Toxicol Lett, 2002,133:33-45.
  • 6Liao WT, Chang KL, Yu CL, et al. Arsenic induces human keratinocyte apoptosis by the FAS/FAS ligand pathway, which correlates with alterations in NF-κB and activator protein-1 activity. J Invest Dermatol, 2004,122:125-129.
  • 7Loennechen T, Mathisen B, Hansen J, et al. Colchicine induces membrane-associated activation of matrix metalloproteinase-2 in osteosarcoma cells in an S100A4-independent manner. Biochem Pharmacol, 2003,66:2341-2353.
  • 8Kiriakidis S, Andreakos E, Monaco C, et al. VEGF expression in human macrophages is NF-κB dependent: studies using adenoviruses expressing the endogenous NF-κB inhibitor IκBα and a kinase-defectiveform of the IκB kinase2.J Cell Sci,2003,116(Pt4):665-674.
  • 9Zhu XH,Shen YL,Jing YK,et al.Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations.J Nat Cancer Inst,1999;91:772-778
  • 10List AF.Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignancies.Oncologist,2001;6(Suppl 5):24-31

共引文献197

同被引文献27

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部